NCT02188264 - Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

April 26, 2019

Conditions

Recurrent Colorectal CarcinomaSolid NeoplasmStage IIIA Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

Interventions

DRUG

Cyclosporine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Selumetinib

Given PO

Trial Locations (10)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

77030

M D Anderson Cancer Center, Houston

80045

UCHealth University of Colorado Hospital, Aurora

95817

University of California Davis Comprehensive Cancer Center, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH